Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Larimar Therapeutics (LRMR) and Cigna (CI)

Tipranks - Tipranks - Wed Feb 25, 7:32AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Larimar Therapeutics (LRMR – Research Report) and Cigna (CI – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Palvella Therapeutics (PVLA)

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Palvella Therapeutics, with a price target of $250.00. The company’s shares closed last Monday at $87.84.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 20.6% and a 47.2% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Palvella Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $187.65, a 120.3% upside from current levels. In a report issued on February 9, H.C. Wainwright also maintained a Buy rating on the stock with a $200.00 price target.

See the top stocks recommended by analysts >>

Larimar Therapeutics (LRMR)

William Blair analyst Myles Minter reiterated a Buy rating on Larimar Therapeutics today. The company’s shares closed last Monday at $2.81, close to its 52-week low of $2.19.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 28.2% and a 58.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Larimar Therapeutics.

Cigna (CI)

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cigna today and set a price target of $355.00. The company’s shares closed last Monday at $283.18.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 14.6% and a 65.1% success rate. Wright covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Phibro Animal Health, and Option Care Health. ;'>

Currently, the analyst consensus on Cigna is a Strong Buy with an average price target of $336.18, representing a 20.5% upside. In a report issued on February 9, TD Cowen also maintained a Buy rating on the stock with a $338.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).